The combination of midostaurin (PKC412) and azacitidine presents a promising therapeutic strategy for elderly patients with acute myelogenous leukemia (AML), particularly those who are unfit for standard induction chemotherapy. Given the increasing incidence of AML in the aging population, this combination therapy could capture a significant share of the market for AML treatments. The trial's completion and subsequent results may enhance the competitive positioning of midostaurin, especially against existing therapies like decitabine and other hypomethylating agents. Diligence should focus on the safety profile, efficacy outcomes, and potential market entry strategies, particularly in light of the evolving landscape of AML treatments and the need for novel therapeutic options for elderly patients.